文献速递白血病

破坏tRNA修饰靶向耐药白血病细胞的线粒体脆弱性

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.
PubMed 文献 · Blood · 2025-01-01

研究通过CRISPR合成致死筛选发现,tRNA甲基转移酶5(TRMT5)介导tRNA反密码子环N1-甲基鸟苷(m1G)形成,对急性髓系白血病(AML)细胞耐受阿糖胞苷和维奈克拉(Ven)至关重要。TRMT5通过其线粒体功能支持线粒体mRNA翻译和氧化磷酸化动态上调,从而维持耐药性;电子传递链基因低表达与近100例初治AML患者诱导治疗预后较差相关。条件性降解TRMT5联合阿糖胞苷和Ven协同诱导耐药AML细胞死亡。

要点

  • TRMT5介导的tRNA m1G修饰是AML细胞耐受阿糖胞苷和维奈克拉所必需。
  • TRMT5促耐药作用依赖其线粒体功能,支持线粒体翻译和氧化磷酸化上调。
  • 条件性降解TRMT5联合阿糖胞苷和Ven协同诱导耐药AML细胞死亡。

核心结论

  • TRMT5是治疗耐药白血病的有前景的药物靶点。

研究设计与样本

  • 研究采用基于CRISPR的合成致死筛选,系统探索RNA修饰在介导抗白血病药物耐药中的作用。

主要发现

  • TRMT5对tRNA反密码子环中m1G的形成至关重要,且是AML细胞耐受阿糖胞苷和维奈克拉所必需。
  • TRMT5甲基化几乎所有线粒体和核tRNA第37位鸟苷,但其促耐药作用特异性依赖线粒体功能。
  • TRMT5对线粒体mRNA翻译和氧化磷酸化的动态上调必不可少,这些过程对维持白血病细胞耐药性至关重要。
  • 在近100例接受首次诱导治疗的AML患者队列中,电子传递链基因低表达与较差预后相关。
  • 使用条件性degron靶向耗竭TRMT5蛋白,联合阿糖胞苷和维奈克拉治疗,协同诱导耐药AML细胞死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dysregulated RNA modifications contribute to cancer progression and therapy resistance, yet the underlying mechanism often remains unknown. Here, we perform CRISPR-based synthetic lethality screens to systematically explore the role of RNA modifications in mediating resistance to antileukemic drugs. We identify the tRNA methyltransferase 5 (TRMT5)-mediated formation of N1-methylguanosine (m1G) in the transfer RNA (tRNA) anticodon loop as essential for mediating drug tolerance to cytarabine and venetoclax (Ven) in acute myeloid leukemia (AML). TRMT5 methylates nearly all mitochondrial and nuclear tRNAs with a guanosine at position 37, but its role in promoting drug tolerance specifically depends on its mitochondrial function. TRMT5 is essential for the dynamic upregulation of mitochondrial messenger RNA translation and oxidative phosphorylation, which are critical for sustaining drug tolerance in leukemia cells. This mitochondrial dependency correlates with therapy outcomes in patients with leukemia: lower expression of electron transport chain genes is linked to poorer outcomes in a cohort of nearly 100 patients with AML undergoing first induction therapy. Finally, we demonstrate that targeted depletion of the TRMT5 protein using a conditional degron, in conjunction with cytarabine and Ven treatment, synergistically induces cell death in drug-tolerant AML cells. Thus, our study reveals TRMT5 as a promising drug target for therapy-resistant leukemia.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pauli C, Kienhöfer M, Blank MF, et al. Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells. Blood. 2025. PMID: 40749163. doi:10.1182/blood.2024027822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。